一分钟看懂
这是一项关于小细胞肺癌的II 期研究，登记的药物或干预包括Tarlatamab，当前状态为研究进行中，已停止招募。登记地点显示中国北京、福州、广州、哈尔滨等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tarlatamab · II 期
登记条件中文摘要
年龄范围：18岁至99岁
登记的基本范围为不限性别，年龄18岁至99岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- Peking Union Medical College Hospital · 北京
- Fujian Cancer Hospital · 福州
- Mengchao Hepatobiliary Hospital of Fujian Medical University · 福州
- Sun Yat-Sen University Cancer Center · 广州
- Affiliated Cancer Hospital of Harbin Medical University · 哈尔滨
- The Second Xiangya Hospital of Central South University · 长沙
- Shanxi Bethune Hospital · 太原
- West China Hospital of Sichuan University · 成都
- Tianjin Medical University Cancer Institute and Hospital · 天津
- Sir Run Run Shaw Hospital · 杭州
- Taizhou Hospital of Zhejiang Province · 台州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Participant has provided informed consent prior to initiation of any study specific activities/procedures.
- * Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent.
- * Histologically or cytologically confirmed SCLC with demonstrated progression or relapse.
- * Participants who progressed or recurred following 1 platinum-based regimen.
- * Measurable disease as defined per RECIST 1.1 within the 21-day screening period.
- * Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
- * Minimum life expectancy of 12 weeks.
- * Adequate organ function as described per protocol.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06745323；登记信息更新于 2026-10-06；本站同步于 2026-10-08。